GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS)HIV Infections
- Interventions
- Drug: E/C/F/TAF (Low Dose)
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 129
- Registration Number
- NCT01854775
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇿🇦Desmond Tutu HIV Foundation, Cape Town, South Africa
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 647
- Registration Number
- NCT01851330
A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 476
- Registration Number
- NCT01850212
- Locations
- 🇩🇪
Universitäts-Hautklinik Essen, Essen, Germany
🇩🇪Universitatsklinik Koln (AöR), Koln, Germany
🇩🇪Klinikum der Universität München-Großhadern, Munchen, Germany
Study of the Effect of GS-6615 in Subjects With LQT-3
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01849003
- Locations
- 🇺🇸
University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT01847391
- Locations
- 🇺🇸
Investigational Site, Madison, Wisconsin, United States
Phase Ib Study of SC Milatuzumab in SLE
- Conditions
- Lupus NephritisLupus Erythematosus, CutaneousLupus Erythematosus, SystemicLupus Erythematosus, DiscoidLupus Vasculitis, Central Nervous System
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 22
- Registration Number
- NCT01845740
- Locations
- 🇺🇸
Cedars Sinai Medical Center-Wallace Rheumatic Study Center, West Hollywood, California, United States
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01843127
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸Translational Research Institute-Florida Hospital, Orlando, Florida, United States
🇺🇸SeaView Research, Inc, Miami, Florida, United States
A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment CDrug: Treatment EDrug: Treatment GDrug: Treatment HDrug: Treatment IDrug: Treatment J
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 56
- Registration Number
- NCT01841489
- Locations
- 🇺🇸
Investigational Site, Daytona Beach, Florida, United States
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-08-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 8
- Registration Number
- NCT01840735
- Locations
- 🇺🇸
Compass Research Phase 1, LLC, Orlando, Florida, United States
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT01838590